0T6G Stock Overview
A clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Q32 Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.69 |
| 52 Week High | US$53.40 |
| 52 Week Low | US$1.38 |
| Beta | 0 |
| 1 Month Change | -13.35% |
| 3 Month Change | -36.77% |
| 1 Year Change | -94.15% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0T6G | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 9.0% | 3.3% | 0.4% |
| 1Y | -94.2% | -13.8% | -0.4% |
Return vs Industry: 0T6G underperformed the UK Biotechs industry which returned -14.9% over the past year.
Return vs Market: 0T6G underperformed the UK Market which returned -0.1% over the past year.
Price Volatility
| 0T6G volatility | |
|---|---|
| 0T6G Average Weekly Movement | 16.3% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: 0T6G's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0T6G's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 29 | Jodie Morrison | www.q32bio.com |
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.
Q32 Bio Inc. Fundamentals Summary
| 0T6G fundamental statistics | |
|---|---|
| Market cap | US$20.13m |
| Earnings (TTM) | -US$59.79m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs 0T6G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0T6G income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$48.25m |
| Gross Profit | -US$48.25m |
| Other Expenses | US$11.54m |
| Earnings | -US$59.79m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.90 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -316.4% |
How did 0T6G perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/15 07:39 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Q32 Bio Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Smith | Leerink Partners LLC |
| Jay Olson | Oppenheimer & Co. Inc. |
| Christopher Raymond | Piper Sandler Companies |